Skip to main content

Table 3 Application, response and survival of systemic therapy

From: Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients

 

Patients

Response

Overall survival

Lines of systemic therapy

n

%

PR*

SD*

NE*

PD*

Median OS

95% CI

1

352

100

30.7

29.0

20.7

19.6

7.6

6.8-8.5

2

183

52.0

14.8

31.7

19.7

33.8

6.2

5.0-7.4

3

97

27.6

12.4

23.7

22.7

41.2

5.2

3.5-7.0

4

48

13.6

14.6

20.8

31.3

33.4

5.1

3.7-6.5

5

20

5.7

5.0

30.0

10

55.0

4.5

1.9-7.1

6

8

2.3

37.5

12.5

12.5

37.5

11.1

3.1-19.1

7

2

0.6

0

0

50

50

  
  1. Survival is stated in months from the beginning of the respective line of systemic therapy. Response was assessed according to RECIST: PR, Partial response; SD, stable disease; NE, not evaluable; PD, progressive disease. CI, confidence interval. OS, overall survival. * Because of rounding, not all percentages sum to 100.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us